



Murine Anti-Factor VIII

Clone GMA-8012

Factor VIII (FVIII) is a heterodimer consisting of a heavy chain (ranging in mass from 90 to 200 kDa) bound via metal ions to a light chain (80 kDa). In plasma, FVIII circulates in an inactive form bound to von Willebrand factor. Following activation by factor Xa or thrombin, factor VIIIa can function as cofactor for the enzyme factor IXa in the activation of factor X in the presence of phospholipid and Ca²⁺. Absent or defective FVIII is the cause of the X-linked recessive bleeding disorder hemophilia A. GMA-8012 recognizes the A1-A3 domain of FVIII, is slightly inhibitory, and is suitable for ELISA and bio-layer interferometry pairing experiments.

Description

Antibody Source:	mouse monoclonal, IgG _{2a}
Antigen Species Bound:	human, porcine, murine
Specificity:	FVIII A1-A3 domain
Immunogen:	B-domain deleted recombinant human FVIII


Formulation and Storage

Purity:	IgG purified by protein G affinity chromatography from serum-free cell culture supernatant.
Product Formulation:	Lyophilized from a ≥1 mg/ml solution in 20 mM NaH ₂ PO ₄ 0.15 M NaCl, 1.0% (w/v) mannitol, pH 7.4. Concentration determined by absorbance measurement at 280 nm and using an extinction coefficient of 1.4 (ε _{0.1%}).
Reconstitution:	Reconstitute with deionized water.
Storage:	Store lyophilized or reconstituted and aliquoted material at -20° C for prolonged periods. Avoid freeze-thaw cycles. Alternatively, add 0.02% (w/v) sodium azide to reconstituted solution and store at 4° C.
Country of origin:	USA
Size Options:	0.1 mg or 0.5 mg

Applications

Working Concentration:	Approximately 1-5 µg/ml. Researcher should titer antibody in specific assay.
ELISA:	Binds immobilized human, porcine, murine FVIII.
Immunoblotting:	Not recommended.
Inhibition:	Slightly inhibitory in aPTT clotting assay.
Bio-layer interferometry:	Pairs with GMA-8001, -8002, -8004, -8005, 8013, 8020.

GMA-8012 binding in ELISA



References

[1] B.R. Long et al. The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy. *Molecular Therapy: Methods & Clinical Development*. (2019). 13:440-452.